Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience

被引:59
作者
Berruti, A
Borasio, P
Gerbino, A
Gorzegno, G
Moschini, T
Tampellini, M
Ardissone, F
Brizzi, MP
Dolcetti, A
Dogliotti, L
机构
[1] 13 Azienda Osped San Luigi, I-10043 Orbassano, Italy
[2] Univ Turin, Dipartiamento Sci Clin & Biol Oncol Med, Turin, Italy
关键词
primary chemotherapy; thymome; radiotherapy;
D O I
10.1038/sj.bjc.6690773
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
From 1990 to 1997, 16 consecutive patients with stage III and IVa invasive thymoma were treated in a single institution with primary chemotherapy consisting in adriamycin (40 mg m(-2)), cisplatin (50 mg m(-2)) administered intravenously on day 1, vincristine (0.6 mg m(-2)) on day 2 and cyclophosphamide (700 mg m(-2) on day 4 (ADOC). The courses were repeated every 3 weeks. The aim was to evaluate the impact of this cytotoxic regimen with respect to response rate, per cent of patients radically resected, time to progression and overall survival. Two complete responses (one clinical and one pathological) and 11 partial responses were observed (overall response rate 81.2%); two patients had stable disease and one progressed. Toxicity was mild as only two patients developed grade III/IV neutropenia and one patient grade III nausea/vomiting. Nine patients were radically resected (five out of ten with stage III, and four out of six with stage IVa). Median time to progression and overall survival was 33.2 and 47.5 months respectively. Three patients were alive and disease free after more than 5 years. The ADOC scheme is highly active and manageable in the treatment of locally advanced thymoma. As a preoperative approach it should be offered to patients not amenable to surgery or to those surgically resectable but with a great deal of morbidity.
引用
收藏
页码:841 / 845
页数:5
相关论文
共 36 条
  • [11] LEWIS JE, 1987, CANCER, V60, P2727, DOI 10.1002/1097-0142(19871201)60:11<2727::AID-CNCR2820601125>3.0.CO
  • [12] 2-D
  • [13] CISPLATIN PLUS DOXORUBICIN PLUS CYCLOPHOSPHAMIDE IN METASTATIC OR RECURRENT THYMOMA - FINAL RESULTS OF AN INTERGROUP TRIAL
    LOEHRER, PJ
    KIM, K
    AISNER, SC
    LIVINGSTON, R
    EINHORN, LH
    JOHNSON, D
    BLUM, R
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (06) : 1164 - 1168
  • [14] Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: An intergroup trial
    Loehrer, PJ
    Chen, M
    Kim, KM
    Aisner, SC
    Einhorn, LH
    Livingston, R
    Johnson, D
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (09) : 3093 - 3099
  • [15] MACCHIARINI P, 1991, CANCER, V68, P706, DOI 10.1002/1097-0142(19910815)68:4<706::AID-CNCR2820680407>3.0.CO
  • [16] 2-H
  • [17] MAGGI G, 1986, CANCER-AM CANCER SOC, V58, P765, DOI 10.1002/1097-0142(19860801)58:3<765::AID-CNCR2820580326>3.0.CO
  • [18] 2-S
  • [19] THYMOMA - RESULTS OF 241 OPERATED CASES
    MAGGI, G
    CASADIO, C
    CAVALLO, A
    CIANCI, R
    MOLINATTI, M
    RUFFINI, E
    [J]. ANNALS OF THORACIC SURGERY, 1991, 51 (01) : 152 - 156
  • [20] MASAOKA A, 1981, CANCER, V48, P2485, DOI 10.1002/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO